Qualité de vie et résultat à court terme après chimiothérapie intra- Peritoneale vaporisée (PIPAC) chez les patients atteints de carcinose péritonéale.

Détails

Ressource 1Télécharger: Thèse_Teixeira-OK.pdf (1054.04 [Ko])
Etat: Serval
Version: Après imprimatur
ID Serval
serval:BIB_7B3997FD7956
Type
Thèse: thèse de doctorat.
Collection
Publications
Titre
Qualité de vie et résultat à court terme après chimiothérapie intra- Peritoneale vaporisée (PIPAC) chez les patients atteints de carcinose péritonéale.
Auteur(s)
TEIXEIRA FARINHA Hugo
Directeur(s)
Hubner Martin
Codirecteur(s)
Demartines Nicolas
Institution
Université de Lausanne, Faculté de biologie et médecine
Adresse
Faculté de biologie et de médecine
Université de Lausanne
CH-1015 Lausanne
SUISSE

Statut éditorial
Acceptée
Date de publication
2017
Langue
français
Résumé
Background. Peritoneal cancer treatment aims to prolong survival, but preserving Quality of Life (QoL) under treatment is also a priority. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) is a novel minimally invasive repeatable treatment modality. The aim of the present study was to assess QoL in our cohort of PIPAC patients. Methods. Analysis of all consecutive patients included from the start of PIPAC program (January 2015). QoL (0-100: optimal) and symptoms (no symptom: 0-100) were
measured prospectively before and after every PIPAC procedure using EORTC QLQ-C30. Results. Forty-two patients (M :F = 8: 34,
median age 66 (59-73) years) had 91 PIPAC procedures in total (1: 4x, 17: 3x, 12:2x, and 12 : lx). Before first PIPAC, baseline QoL was measured as median of 66 ± 2.64. Prominent complaints were fatigue (32 ± 4.3) and digestive symptoms as diarrhea (17 ± 3.75),
constipation (17 ± 4.13), and nausea (7 ± 2.54). Overall Quality of Life was 64 ± 3.75 after PIPAC#l (p = 0.57), 61 ± 4.76 after
PIPAC#2 (p = 0.89), and 70 ± 6.67 after PIPAC#3 (p = 0.58). Fatigue symptom score was 44 ± 4.86 after PIPAC#l and 47 ± 6.69
and 34 ± 7.85 after second and third applications, respectively (p = 0.40). Diarrhea (p = 0.31), constipation (p = 0.76), and nausea (p = 0.66) did not change significantly under PIPAC treatment. Conclusion. PIPAC treatment of peritoneal carcinomatosis had no negative impact on patients' overall QoL and its components or on main symptoms. This study was registered online on Research Registry (UIN: 1608).

Création de la notice
30/05/2017 11:51
Dernière modification de la notice
03/03/2018 18:35
Données d'usage